Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Immunodeficiency disorders; Inflammation
- Focus Adverse reactions; Proof of concept
- 18 Oct 2018 Status changed from recruiting to suspended.
- 03 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Jul 2018 to 6 Jul 2018.
- 28 Jun 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 26 Jun 2018 to 4 Jul 2018.